Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript

Core Viewpoint - Collegium Pharmaceutical is expanding its position in the ADHD market through the acquisition of AZSTARYS and related subsidiaries from Corium Therapeutics [2] Group 1: Acquisition Details - The acquisition of AZSTARYS significantly enhances Collegium's portfolio in the ADHD sector [2] - The call includes participation from key executives, including the President and CEO, Chief Commercial Officer, and Chief Financial Officer, indicating a strong leadership presence for the discussion [2] Group 2: Investor Communication - The company emphasizes that the information presented is not promotional and includes forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995 [3] - There is a caution regarding the potential differences between future results and current expectations, highlighting the inherent risks and uncertainties [4]